Abstract: The present invention relates to a method of designing an inhibitor of the binding of HIV (human immunodeficiency virus) glycoprotein (gp)120 to a CD4-receptor or to the integrin alpha4 beta7 (a4b7). The inhibitor interacts with at least two amino acid residues comprised in six motifs within the 3-dimensional structure of gp120. Also provided are compounds, pharmaceutical compositions thereof and uses thereof in the development of an inhibitor of the binding of a HIV gp120 to a CD4-receptor or an integrin alpha4 beta7 (a4b7). The inhibitors are useful for the prevention or treatment of an HIV infection and/or diseases associated with an HIV infection.
Type:
Grant
Filed:
July 12, 2016
Date of Patent:
October 9, 2018
Assignee:
KFLP BIOTECH, LLC
Inventors:
Andrey Vinnik, Peter Fedichev, Maxim Kholin, Christopher Molloy, Aron Katz
Abstract: The present invention provides compounds and pharmaceutical compositions for use in treating or preventing retroviral infections, in particular HIV infections and/or diseases associated with an HIV infection.
Type:
Grant
Filed:
September 26, 2013
Date of Patent:
April 4, 2017
Assignee:
KFLP BIOTECH, LLC
Inventors:
Andrey Vinnik, Peter Fedichev, Maxim Kholin, Christopher Molloy, Aron Katz, Alexander Kadushkin
Abstract: The present invention relates to a method of designing an inhibitor of the binding of HIV (human immunodeficiency virus) glycoprotein (gp)120 to a CD4-receptor or to the integrin alpha4 beta7 (a4b7). The inhibitor interacts with at least two amino acid residues comprised in six motifs within the 3-dimensional structure of gp120. Also provided are compounds, pharmaceutical compositions thereof and uses thereof in the development of an inhibitor of the binding of a HIV gp120 to a CD4-receptor or an integrin alpha4 beta7 (a4b7). The inhibitors are useful for the prevention or treatment of an HIV infection and/or diseases associated with an HIV infection.
Type:
Grant
Filed:
October 27, 2011
Date of Patent:
August 23, 2016
Assignee:
KFLP BIOTECH, LLC
Inventors:
Andrey Vinnik, Peter Fedichev, Maxim Kholin, Christopher Molloy, Aron Katz
Abstract: The present invention relates to a method of designing an inhibitor of the binding of HIV (human immunodeficiency virus) glycoprotein (gp)120 to a CD4-receptor or to the integrin alpha4 beta7 (a4b7). The inhibitor interacts with at least two amino acid residues comprised in six motifs within the 3-dimensional structure of gp120. Also provided are compounds, pharmaceutical compositions thereof and uses thereof in the development of an inhibitor of the binding of a HIV gp120 to a CD4-receptor or an integrin alpha4 beta7 (a4b7). The inhibitors are useful for the prevention or treatment of an HIV infection and/or diseases associated with an HIV infection.
Type:
Application
Filed:
October 27, 2011
Publication date:
February 6, 2014
Applicant:
KFLP BIOTECH, LLC
Inventors:
Andrey Vinnik, Peter Fedichev, Maxim Kholin, Christopher Molloy, Aron Katz